Harte Hanks (HHS) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Q3 2024 revenue increased 1.1% year-over-year to $47.6 million, led by growth in Customer Care and Sales Services, while Marketing and Fulfillment & Logistics declined.
Operating income was $1.9 million, down from $2.9 million in Q3 2023, with a 4.0% margin, impacted by restructuring and higher sales/marketing investment.
Net income was $0.1 million ($0.02 per share), compared to $0.6 million ($0.09 per share) in Q3 2023; nine-month net loss was $27.9 million due to a $37.5 million pension charge.
Project Elevate transformation program is underway, targeting $16 million in cost savings by end of 2025, with $6 million in 2024 and $0.8 million in Q3 restructuring charges.
Strategic focus on sustainable growth, free cash flow optimization, and leveraging data and AI through the new Customer Excellence and Growth division.
Financial highlights
Q3 2024 revenue: $47.6 million (+1.1% YoY); operating income: $1.9 million (down from $2.9 million YoY); net income: $0.1 million ($0.02/share).
Adjusted operating income was $3.1 million, nearly flat year-over-year; adjusted EBITDA was $4.1 million, with a stable margin of 8.7%.
Cash and cash equivalents were $5.9 million as of September 30, 2024, and $9.8 million as of October 31, 2024; $24 million available on credit line.
No outstanding debt; $25 million credit facility remains undrawn.
Capital expenditures for nine months were $3.1 million.
Outlook and guidance
Q4 2024 revenue is expected to decline low to mid-single digits due to customer program changes, but management is confident in expanding the client base and driving sustainable growth.
Project Elevate is on track to deliver $6 million in 2024 savings and $16 million by end of 2025.
Focus remains on growing free cash flow and leveraging new organizational structures.
Latest events from Harte Hanks
- Q2 2026 saw a net loss of $5.0M and a pending acquisition by Star Equity Holdings.HHS
Q2 2026 - All director nominees, Say on Pay, and auditor ratification proposals were approved by majority vote.HHS
AGM 2026 - Revenue fell 10.3% and net loss widened, but strong liquidity supports a positive outlook.HHS
Q1 2026 - Operational improvements, governance enhancements, and key votes position the company for growth.HHS
Proxy filing - Positive EBITDA and improved net results in FY 2025 despite lower revenue and segment declines.HHS
Q4 2025 - Shareholders to vote on board, executive pay, and auditor as company targets growth and innovation.HHS
Proxy Filing - Beneficial ownership update adds Rosenbachs as 26.26% holders for 2025 meeting.HHS
Proxy Filing - Q3 2025 revenue dropped 17% with net loss, but cost controls and new deals support outlook.HHS
Q3 2025 - Q2 net loss of $27.8M from pension charge; Sales Services surged, cash strong, no debt.HHS
Q2 2024